Top

Published in:

01-04-2020 | Peritonectomy | Original Article

Risk factors and management of incisional hernia after cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal surface malignancies

Authors: P. A. Cascales Campos, A. González-Gil, A. J. Gómez-Ruiz, E. Gil-Gómez, F. Alconchel-Gago, A. Navarro-Barrios, J. Martínez-García, J. L. Alonso-Romero, A. Nieto, F. Barceló-Valcarcel, J. Gil-Martínez

Published in: Hernia | Issue 2/2020

Abstract

Background

The incidence of incisional hernia in patients with peritoneal surface malignancies treated by cytoreduction plus hyperthermic intraperitoneal chemotherapy (HIPEC) remains unclear, and the criteria commonly used to indicate their repair cannot be applied in these patients. The objective of this work was to analyze the incidence of incisional hernias in these patients, identify the risk factors associated with their appearance, and propose an algorithm for their management.

Methods

We analyzed a series of patients with malignant pathologies of the peritoneal surface treated by cytoreduction with peritonectomy and HIPEC procedures between January 2008 and June 2017. Only patients with a minimum postoperative follow-up period of 12 months were included.

Results

Our series included 282 patients, 28 (10%) of whom developed an incisional hernia during the follow-up period. Fifty-one patients, all with ovarian cancer with peritoneal dissemination, did not receive HIPEC after cytoreduction as they were part of the control arm of the CARCINOHIPEC clinical trial (NCT02328716) or because they did not provide specific informed consent. In the multivariate analysis, treatment with HIPEC (OR 2.56, 95% CI [1.57, 4.31], p = 0.032) and the administration of preoperative systemic chemotherapy (OR = 1.59, 95% CI [1.26, 3.58], p = 0.041) were found to be independent factors related to the appearance of an incisional hernia.

Conclusions

The incidence of incisional hernia after cytoreduction and HIPEC is within the ranges described in the literature for other abdominal surgery procedures. The use of systemic chemotherapy and treatment with HIPEC, in particular, were identified as factors related to their occurrence.

Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J et al (2000) Peritoneal carcinomatosis from non-gynecologic malignancies. Cancer 88(2):358–363CrossRef

Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221(1):29–42CrossRef

Deraco M, Baratti D, Inglese MG, Allaria B, Andreola S, Gavazzi C et al (2004) Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol 11(4):393–398CrossRef

Deraco M, Casali P, Inglese MG, Baratti D, Pennacchioli E, Bertulli R et al (2003) Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol 83(3):147–153CrossRef

Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H (2008) 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 15(9):2426–2432CrossRef

www.clinicaltrials.gov. NCT00769405. Accessed 10 Jan 2019

Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M et al (2018) A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. JCO 36(18_suppl):LBA3503–LBA3503CrossRef

van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM et al (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378(3):230–240CrossRef

Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E et al (2015) Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 22(5):1570–1575CrossRef

10.

Halkia E, Kopanakis N, Nikolaou G, Spiliotis J (2015) Cytoreductive surgery and HIPEC for peritoneal carcinomatosis. A review on morbidity and mortality. J BUON 20 Suppl 1:S80–S87PubMed

11.

Lauscher JC, Rieck S, Loh JC, Gröne J, Buhr HJ, Ritz J-P (2011) Oligosymptomatic vs. symptomatic incisional hernias—who benefits from open repair? Langenbecks Arch Surg 396(2):179–185CrossRef

12.

Yahchouchy-Chouillard E, Aura T, Picone O, Etienne J-C, Fingerhut A (2003) Incisional hernias. DSU 20(1):3–9

13.

Cascales-Campos PA, Gil J, Feliciangeli E, Gil E, González-Gil A, López V et al (2015) The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction. Ann Surg Oncol 22(3):987–993CrossRef

14.

Cascales-Campos PA, Gil J, Gil E, Feliciangeli E, González-Gil A, Parrilla JJ et al (2014) Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer. Ann Surg Oncol 21(7):2383–2389CrossRef

15.

Cascales Campos P, Gil J, Parrilla P (2014) Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer. Eur J Surg Oncol 40(8):970–975CrossRef

16.

Long KC, Levinson KL, Diaz JP, Gardner GJ, Chi DS, Barakat RR et al (2011) Ventral hernia following primary laparotomy for ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol 120(1):33–37CrossRef

17.

Colavita PD, Tsirline VB, Belyansky I, Walters AL, Lincourt AE, Sing RF et al (2012) Prospective, long-term comparison of quality of life in laparoscopic versus open ventral hernia repair. Ann Surg 256(5):714CrossRef

18.

Eriksen JR, Poornoroozy P, Jørgensen LN, Jacobsen B, Friis-Andersen HU, Rosenberg J (2009) Pain, quality of life and recovery after laparoscopic ventral hernia repair. Hernia 13(1):13–21CrossRef

19.

Stey AM, Danzig M, Qiu S, Yin S, Divino CM (2014) Cost-utility analysis of repair of reducible ventral hernia. Surgery 155(6):1081–1089CrossRef

20.

Yu G, Tang B, Yu P-W, Peng Z, Qian F, Sun G (2010) Systemic and peritoneal inflammatory response after laparoscopic-assisted gastrectomy and the effect of inflammatory cytokines on adhesion of gastric cancer cells to peritoneal mesothelial cells. Surg Endosc 24(11):2860–2870CrossRef

21.

Sugarbaker PH (2017) Management of an inguinal hernia in patients with pseudomyxoma peritonei. Eur J Surg Oncol 43(6):1083–1087CrossRef

22.

Shigeyoshi I, Komori K, Kinoshita T, Oshiro T, Ito S, Abe T et al (2018) Peritoneal cecal cancer metastasis to a mesh‐plug prosthesis: a case report. J Med Invest 65(1.2):142–146CrossRef

23.

Kudou M, Murayama Y, Konishi H, Morimura R, Komatsu S, Shiozaki A et al (2015) Peritoneal colon cancer metastasis to bilateral inguinal hernia repair sites: report of a case. Surg Today 45(8):1053–1057CrossRef

24.

Bouillot J-L, Aouad K, Alexandre J-H (1999) Parietal mesh abscess as an original presentation of cancer of the caecum. DSU 16(2):158–160

25.

Guerry L, Ullah M, Kaci R, Pocard M, Lo Dico R (2018) Biosinthetic mesh increases peritoneal metástasis growth in animal model, the biological mesh does not! Pleura Peritoneum 3(Suppl):1. https://doi.org/10.1515/pap-2018-7005 CrossRef

Title: Risk factors and management of incisional hernia after cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal surface malignancies
Authors: P. A. Cascales Campos
A. González-Gil
A. J. Gómez-Ruiz
E. Gil-Gómez
F. Alconchel-Gago
A. Navarro-Barrios
J. Martínez-García
J. L. Alonso-Romero
A. Nieto
F. Barceló-Valcarcel
J. Gil-Martínez
Publication date: 01-04-2020
Publisher: Springer Paris
Keywords: Peritonectomy
Ovarian Cancer
Ovarian Cancer
Incisional Hernia
Peritoneal Cancer
Peritoneal Carcinomatosis
Cytostatic Therapy
Published in: Hernia / Issue 2/2020
Print ISSN: 1265-4906
Electronic ISSN: 1248-9204
DOI: https://doi.org/10.1007/s10029-019-01962-4

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Risk factors and management of incisional hernia after cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal surface malignancies

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2020

Long-term impact of incisional hernia on quality of life after colonic cancer resection

Quality of life and parastomal hernia repair: the PROPHER study

En bloc removal of infected hernia mesh rather than “blue-ectomy”

The management of perineal hernia following abdomino-perineal excision for cancer

A 25 year experience of perineal hernia repair

Use of autologous dermal flap as mesh coverage in the treatment of large abdominal-wall defect in patients following massive weight loss: presentation of a novel surgical technique